ロード中...
Per cent of patients with chronic migraine who responded per onabotulinumtoxinA treatment cycle: PREEMPT
OBJECTIVE: The approved use of onabotulinumtoxinA for prophylaxis of headaches in patients with chronic migraine (CM) involves treatment every 12 weeks. It is currently unknown whether patients who fail to respond to the first onabotulinumtoxinA treatment cycle will respond to subsequent treatment c...
保存先:
| 出版年: | J Neurol Neurosurg Psychiatry |
|---|---|
| 主要な著者: | , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
BMJ Publishing Group
2015
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4552933/ https://ncbi.nlm.nih.gov/pubmed/25500317 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/jnnp-2013-307149 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|